scholarly journals Treatment Experience of 210 Pediatric Patients With Extraordinary Daytime Urinary Frequency: A Prospective Study

2021 ◽  
Vol 9 ◽  
Author(s):  
Yan Li ◽  
Ying Zhang ◽  
Chao Liu ◽  
Xiang Li ◽  
Qi Zhou ◽  
...  
Keyword(s):  
Treatment Group ◽  
Combination Therapy ◽  
Drug Treatment ◽  
Prospective Study ◽  
Response Rate ◽  
Therapy Group ◽  
Urinary Frequency ◽  
Bowel Movements ◽  
A Prospective Study ◽  
Drug Treatment Group

Background: Lactulose can be used to manage chronic constipation and children who are withholding their bowel movements, but no studies are available regarding lactulose to treat pediatric extraordinary daytime urinary frequency (PEDUF). To explore the benefits of different therapeutic regimens (non-drug treatment vs. oral lactulose) in patients with PEDUF.Methods: This prospective study included PEDUF patients admitted to the Pediatric Center of Qilu Hospital of Shandong University (Qingdao) from January 2015 to December 2019. The patients randomized received non-drug treatment (counseling), drug treatment (lactulose), or combination therapy. A therapeutic effect was defined by a decrease of>10% of the urination frequency.Results: A total of 210 patients were included. They were 5.9 ± 0.4 years. There were 98 boys and 112 girls. Among the 210 patients, 82.4% (173/210) of their family members reported symptoms of constipation. Among the three groups, the response rate was 61.4% (43/70) in the non-drug treatment group, 90.0% (63/70) in the drug treatment group, and 91.4% (64/70) in the combination therapy group (P < 0.0001).Conclusion: The frequency of constipation in children with PEDUF is high. The use of a laxative, like lactulose, might achieve a high therapeutic response rate in children with PEDUF, higher than counseling alone. That might represent a valuable therapeutic strategy for PEDUF.

330 - Combination Therapy of Cyclosporine and Vedolizumab is Effective and Safe for Severe, Steroid-Resistant Ulcerative Colitis Patients: A Prospective Study

2018 ◽  
Vol 154 (6) ◽  
pp. S-82-S-83 ◽  
Author(s):  
Dino Tarabar ◽  
Katia El Jurdi ◽  
Olivia Yvellez ◽  
Zoran Milenkovic ◽  
Stanko Petrovic ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Combination Therapy ◽  
Prospective Study ◽  
Steroid Resistant ◽  
A Prospective Study

scholarly journals Effect of regional arterial infusion combined with early enteral nutrition on severe acute pancreatitis

2019 ◽  
Vol 47 (12) ◽  
pp. 6235-6243
Author(s):  
Xiaojuan Wang ◽  
Jinbu Xu ◽  
Jiguang Li ◽  
Yajuan Cheng ◽  
Lu Liu ◽  
...  
Keyword(s):  
Treatment Group ◽  
Combination Therapy ◽  
Conventional Treatment ◽  
Therapy Group ◽  
Early Enteral Nutrition ◽  
Combination Therapy Group ◽  
Arterial Infusion ◽  
Conventional Treatment Group ◽  
Effectiveness Rate ◽  
Biochemical Indices

Objective To measure the therapeutic effects of regional arterial infusion (RAI) in combination with early enteral nutrition (EEN) in patients with severe acute pancreatitis (SAP). Methods A prospective randomized controlled study enrolled patients with SAP. They were randomly divided into a conventional treatment group that served as the control and a combination therapy group that received RAI combined with EEN. The Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) scores, the levels of serum biochemical indices, functional recovery, the incidence of complications and total effectiveness rate were evaluated. Results A total of 100 patients were enrolled in the study. The APACHE II scores and the concentrations of blood glucose, serum amylase, white blood cell count, C-reactive protein, tumour necrosis factor-α, interleukin (IL)-6, IL-10 and IL-17 were significantly decreased, while albumin and serum calcium and total effectiveness rate in the combination therapy group were significantly higher than in the conventional treatment group. The combination therapy group had a significantly reduced time to abdominal pain relief, time of first defaecation, hospital stay and incidence of complications compared with the conventional treatment group. Conclusion The combination of RAI and EEN improved clinical biochemical indices, reduced the incidence of complications and promoted early recovery in patients with SAP.

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5181-5181 ◽  
Author(s):  
Cristina Gasparetto ◽  
George P. Keogh ◽  
Jon P. Gockerman ◽  
Mitchell Horwitz ◽  
Joseph O. Moore ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Prospective Study ◽  
Partial Remission ◽  
Response Rate ◽  
High Dose ◽  
The Usa ◽  
M Spike ◽  
A Prospective Study ◽  
Stem Cell Collection

Abstract The standard induction chemotherapy for patients with multiple myeloma (MM) is a dexamethasone based regimen including dexamethasone alone, VAD, thalidomide+dexamethasone and other combinations. Currently the overall response rate achieved with these regimens is ≤70% and the complete remission (CR) rate is <10%. In order to improve the CR rate for both transplant and non-transplant candidates, other agents and regimens are being explored. Bortezomib (Velcade), a proteasome inhibitor currently approved in the USA and in Europe for the treatment of relapsed/refractory MM, has demonstrated an impressive activity in the treatment of myeloma. In relapsed/refractory MM, bortezomib has achieved response rate of 35%, with a median duration of response and overall survival of 14 and 18 months, respectively. Clinical experience in relapsed/refractory MM and in previously untreated patients has suggested that the combination of bortezomib with other anti-myeloma drugs could further improve the results achieved with bortezomib alone. We have recently initiated a prospective study to assess the combination of velcade, melphalan and prednisone (MPV) in patients with previously untreated MM. The primary objectives of this study are toxicity, feasibility and CR rate after 4 cycles. The regimen consisted of bortezomib 1.3 mg/m2 iv on day 1,4,8,11. melphalan 6 mg/m2 po, and prednisone 60 mg/m2 po given on days 1 through 7 of each cycle. As July 2005, 11 patients have been recruited. The median age is 64 (48–74) and all patients were Durie-Salmon stage IIIA. Nine of the 11 patients have completed ≥2 cycles of therapy, 6 patients have completed all 4 cycles of therapy and 3 patients were withdrawn from study (2 for pneumonia and 1 for grade 3 orthostatic hypotension). The most common adverse events were neuropathy (grade 1–3), neutropenia (grade 1–3), thrombocytopenia (grade1–3), fatigue, and bowel changes. For the 6 patients that have completed all 4 cycles of MPV, the responses were: 2/6 CR (negative SPEP/IFE); 1/6 very good partial remission (VGPR, 90% reduction of M-spike) and 3/6 partial remission (PR, 50% reduction of the serum M-spike). For the 3 patients who have completed only 2 cycles of therapy so far, 1/3 achieved a VGPR and 2/3 achieved a PR. Three patients have proceeded to stem cell collection and all engrafted following high dose therapy. Although experience is still limited and follow-up short, other than 3 patients withdrawn from study, all patients treated with MPV have responded to treatment and 2/6 patients achieved a CR. The best response was observed after cycle 2 in the majority of patients. Stem cell collection and engraftment was successful in all attempts so far. These data indicate that bortezomib combined with a short term alkylating regimen should be further explored as an induction regimen before transplantation in patients with myeloma.

Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up

2016 ◽  
Vol 41 (8) ◽  
pp. 852-857 ◽  
Author(s):  
C. Dessinioti ◽  
C. Zisimou ◽  
V. Tzanetakou ◽  
A. Stratigos ◽  
C. Antoniou
Keyword(s):  
Combination Therapy ◽  
Prospective Study ◽  
Hidradenitis Suppurativa ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document